Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase or coatings may further comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof.

Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.

Abstract: Disclosed are devices, systems, and methods for producing broad spectrum disinfectants, sanitizers, cleaner and deodorizers using chlorine dioxide compositions, and more particularly, to methods for producing chlorine dioxide compositions having improved long term stability by the proper choice of pH and through the careful choice of other product formula ingredients.

Abstract: The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: There is provided a petrolatum substitute. The petrolatum substitute preparation comprises 1-20 wt % of at least one oil thickening agent, 7-40 wt % of at least one structuring agent, 0.5-10 wt % of at least one phytosterol or ester thereof, and 30-92 wt % of at least one emollient, wherein the preparation has a melting point of 35° C. or more. The petrolatum substitute preparation can be used in essentially all applications where petrolatum is used today. The substitute can be made renewable and the use of over-exploited natural products is minimized. The preparation is less irritant and has excellent moisture barrier properties when applied to human skin. Further it is less energy consuming to manufacture.

Abstract: Described herein are antimicrobial copolymers comprising (i) a polymer backbone and a plurality of thiouronium groups covalently bonded to the polymer backbone and (ii) a plurality of quaternary ammonium groups covalently bonded to the polymer backbone. Also described herein are methods for making the copolymers described herein and their use in disinfecting compositions.

Abstract: The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.

Abstract: A method of manufacturing a surgical device including providing a substrate having opposite first and second sides. The second side having a first section and a second section. Coupling a substrate to a fixture such that the first side faces the fixture and depositing a gel onto the second side such that the gel coats the first section without coating the second section.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.

Abstract: An implantable medical device is disclosed comprising a thermoplastic composite body having anterior, first lateral, second lateral, posterior, superior, and inferior surfaces, and at least one dense portion and at least one porous portion which are integrally formed. The at least one dense portion is formed of a first thermoplastic polymer matrix that is essentially non-porous, and which is continuous through a thickness dimension from the superior surface to the inferior surface. The at least one porous portion is formed of a porous thermoplastic polymer scaffold having a second thermoplastic polymer matrix which is continuous through the thickness dimension. A method for forming the thermoplastic composite body is disclosed comprising disposing a first powder mixture in a first portion of a mold, disposing a second powder mixture in a second portion of the mold, simultaneously molding the first powder mixture and the second powder mixture, and leaching porogen.

Abstract: Various embodiments discussed in the present document relate to an implant assembly. The implant assembly includes a porous metal coating. The implant assembly further includes a biocompatible implant material. A polymeric binder layer is disposed between the porous metal coating and the biocompatible implant material.

Abstract: A capsule shell contains 40 to 99% by weight of a core-shell polymer and 1 to 60% by weight of a cellulose. The core-shell polymer contains 50 to 90% by weight of a core, containing polymerized units of 65 to 75% by weight of ethyl acrylate and 25 to 35% by weight of methyl methacrylate; and 10 to 50% by weight of a shell, containing polymerized units of 45 to 55% by weight of ethyl acrylate and 45 to 55% by weight of methacrylic acid.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention is a composition for increasing alcohol metabolism wherein the composition of the present invention is provided in a food substance and a drink formula. The embodiments of the composition of the present invention are operable to increase the alcohol metabolism of a user and also assist the body in burning the carbohydrates and sugars associated with alcohol consumption. The base of the composition of the present invention includes hydrous sodium aluminosilicate. Several embodiments of the present invention are provided wherein these embodiments can include some of the Vitamin B complex as well as hemp protein powder, calcium carbonate and magnesium oxide. The compositions of the present invention further include use of orthosilicates, Vitamin E, calcium, wheat grass, resveratrol, turmeric and theanine. The compositions of the present invention are provided in both liquid and solid forms.

Abstract: The present invention refers to an edible composition comprising water and/or at least one edible oil and a surface reacted calcium carbonate having a volume median particle size d50 from 0.1 to 90 ?m, an edible coating and/or filling comprising the surface-reacted calcium carbonate, a food product or pharmaceutical product or neutraceutical product at least partially coated and/or filled with the edible composition, a method for producing a food product or pharmaceutical product or neutraceutical product at least partially coated and/or filled with the edible composition.

Abstract: The disclosure provides products configured for oral use and methods for preparing such products. In some embodiments, oral products described herein may comprise an active ingredient in an amount of 10 weight percent or less, a sugar alcohol, and a gum, such that the product is in the form of a pastille. In some embodiments, oral products described herein may comprise an active ingredient in an amount of about 10 weight percent or less, a sugar substitute, and a sugar alcohol syrup, such that the product is in the form of a lozenge.

Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.